Acumen Pharmaceuticals, Inc.
ABOS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001576885
No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 57 | 2 | 47 | −8 |
| Shares | 27.1M | 19.6K | 25.6M | −1.46M (−5.4%) |
| Value | $106.1M | $77.0K | $120.5M | +$14.5M (+13.6%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 587,583 | $2.76M | 0.00% |
| Susquehanna International Group, LLP | 26,174 | $123.0K | 0.00% |
| Virtu Financial LLC | 26,204 | $123.0K | 0.01% |
| Qube Research & Technologies Ltd | 22,259 | $105.0K | 0.00% |
| Two Sigma Investments, LP | 15,311 | $72.0K | 0.00% |
| Boothbay Fund Management, LLC | 12,727 | $60.0K | 0.00% |
| Ergoteles LLC | 11,113 | $52.0K | 0.00% |
| LMR Partners LLP | 10,092 | $47.0K | 0.00% |
| Simplex Trading, LLC | 2,672 | $12.0K | 0.00% |
| Credit Suisse AG | 15 | $0 | 0.00% |
| Advisor Group Holdings, Inc. | 1 | $0 | 0.00% |
Sold out (19)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| BVF Inc | 289,663 | $1.13M |
| Pura Vida Investments, LLC | 145,195 | $568.0K |
| Bank of New York Mellon Corp | 68,971 | $270.0K |
| Charles Schwab Investment Management Inc | 63,251 | $248.0K |
| Nuveen Asset Management, LLC | 39,241 | $235.0K |
| Los Angeles Capital Management LLC | 56,592 | $221.0K |
| Point72 Asset Management, L.P. | 55,054 | $215.0K |
| STRS Ohio | 41,300 | $161.0K |
| Rhumbline Advisers | 20,273 | $79.0K |
| Deutsche Bank AG | 15,501 | $61.0K |
| American International Group, Inc. | 14,047 | $55.0K |
| California State Teachers Retirement System | 12,162 | $48.0K |
| Manufacturers Life Insurance Company, The | 12,200 | $47.7K |
| UBS Group AG | 5,245 | $21.0K |
| Amalgamated Bank | 3,896 | $15.0K |
| Legal & General Group Plc | 2,762 | $11.0K |
| Ameritas Investment Partners, Inc. | 2,205 | $9.00K |
| Royal Bank of Canada | 1,739 | $7.00K |
| FinTrust Capital Advisors, LLC | 20 | $0 |
Not filed for Q2 2022 yet (2)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 15,736 | $62.0K |
| Amalgamated Financial Corp. | 3,896 | $15.0K |